Bayer 3rd-qtr boosted by pharma; beats expectations

26 October 2016

Germany’s Bayer (BAYN: DE) reports this morning that third-quarter 2016 profit before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off items, rose 6% to 2.68 billion euros ($2.91 billion), exceeding the average estimate of 2.52 billion euros in a Reuters poll of analysts.

Net profits increased 18.8% to 1.2 billion euros for the three months. Analysts surveyed by Factset had predicted profits of 1.08 billion euros. Core earnings per share increased by 2.4% to 1.73 euros. Notwithstanding that the results beat expectations, Bayer’s shares were down 1.55% to 90.08 euros by mid-morning.

Sales of the Bayer Group increased by 2.3% (Fx & portfolio adj 3.5%) in the third quarter to 11.26 billion euros. Growth was driven by the firm's prescription drugs division, which boosted its underlying profit 16.5% to 1.1 billion euros on stronger sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK